
Margaret Page
Examiner (ID: 19318)
| Most Active Art Unit | 1206 |
| Art Unit(s) | 1208, 1206 |
| Total Applications | 230 |
| Issued Applications | 179 |
| Pending Applications | 3 |
| Abandoned Applications | 48 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18610888
[patent_doc_number] => 20230277618
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => THERAPEUTIC TARGETING OF PHOSPHATE DYSREGULATION IN CANCER VIA THE XPR1:KIDINS220 PROTEIN COMPLEX
[patent_app_type] => utility
[patent_app_number] => 18/019851
[patent_app_country] => US
[patent_app_date] => 2021-08-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49287
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18019851
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/019851 | THERAPEUTIC TARGETING OF PHOSPHATE DYSREGULATION IN CANCER VIA THE XPR1:KIDINS220 PROTEIN COMPLEX | Aug 8, 2021 | Pending |
Array
(
[id] => 17414073
[patent_doc_number] => 20220048977
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-17
[patent_title] => POLYMERIC FORMS OF H-NOX PROTEINS
[patent_app_type] => utility
[patent_app_number] => 17/397577
[patent_app_country] => US
[patent_app_date] => 2021-08-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46758
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17397577
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/397577 | Polymeric forms of H-NOX proteins | Aug 8, 2021 | Issued |
Array
(
[id] => 18596035
[patent_doc_number] => 20230270826
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => ANTIVIRAL USE OF LIRAGLUTIDE AND GEFITINIB
[patent_app_type] => utility
[patent_app_number] => 18/017847
[patent_app_country] => US
[patent_app_date] => 2021-07-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7610
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18017847
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/017847 | ANTIVIRAL USE OF LIRAGLUTIDE AND GEFITINIB | Jul 29, 2021 | Abandoned |
Array
(
[id] => 17443756
[patent_doc_number] => 20220064261
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-03
[patent_title] => MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/384095
[patent_app_country] => US
[patent_app_date] => 2021-07-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46460
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17384095
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/384095 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | Jul 22, 2021 | Abandoned |
Array
(
[id] => 17628521
[patent_doc_number] => 20220163536
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-26
[patent_title] => IDENTIFYING PEPTIDES AT THE SINGLE MOLECULE LEVEL
[patent_app_type] => utility
[patent_app_number] => 17/384118
[patent_app_country] => US
[patent_app_date] => 2021-07-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12839
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17384118
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/384118 | IDENTIFYING PEPTIDES AT THE SINGLE MOLECULE LEVEL | Jul 22, 2021 | Abandoned |
Array
(
[id] => 17460141
[patent_doc_number] => 20220073446
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-10
[patent_title] => Antigen Delivery Vectors and Constructs
[patent_app_type] => utility
[patent_app_number] => 17/379439
[patent_app_country] => US
[patent_app_date] => 2021-07-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6600
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17379439
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/379439 | Antigen Delivery Vectors and Constructs | Jul 18, 2021 | Abandoned |
Array
(
[id] => 18597215
[patent_doc_number] => 20230272009
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => Peptide, Peptide Salt, Pharmaceutical Composition and Biological Tissue Calcification Inhibitor
[patent_app_type] => utility
[patent_app_number] => 18/016660
[patent_app_country] => US
[patent_app_date] => 2021-07-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7328
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18016660
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/016660 | Peptide, Peptide Salt, Pharmaceutical Composition and Biological Tissue Calcification Inhibitor | Jul 15, 2021 | Pending |
Array
(
[id] => 17356806
[patent_doc_number] => 20220017602
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-20
[patent_title] => OCULAR COMPOSITIONS AND METHODS
[patent_app_type] => utility
[patent_app_number] => 17/377159
[patent_app_country] => US
[patent_app_date] => 2021-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26940
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17377159
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/377159 | OCULAR COMPOSITIONS AND METHODS | Jul 14, 2021 | Pending |
Array
(
[id] => 18537512
[patent_doc_number] => 20230242607
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-03
[patent_title] => IL-2 VARIANTS
[patent_app_type] => utility
[patent_app_number] => 18/004575
[patent_app_country] => US
[patent_app_date] => 2021-07-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13741
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -45
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18004575
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/004575 | IL-2 VARIANTS | Jul 6, 2021 | Pending |
Array
(
[id] => 18581643
[patent_doc_number] => 20230263896
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-24
[patent_title] => NOVEL POLYPEPTIDE AND THERAPEUTIC USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/015029
[patent_app_country] => US
[patent_app_date] => 2021-07-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20004
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 544
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18015029
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/015029 | NOVEL POLYPEPTIDE AND THERAPEUTIC USE THEREOF | Jul 5, 2021 | Pending |
Array
(
[id] => 18596025
[patent_doc_number] => 20230270816
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => COMBINATION OF ANTINEOPLASTIC ANTIBIOTICS AND BCL-2 INHIBITORS FOR THE TREATMENT OF NPM-1-DRIVEN ACUTE MYELOID LEUKEMIA (AML)
[patent_app_type] => utility
[patent_app_number] => 18/004338
[patent_app_country] => US
[patent_app_date] => 2021-07-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6782
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18004338
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/004338 | COMBINATION OF ANTINEOPLASTIC ANTIBIOTICS AND BCL-2 INHIBITORS FOR THE TREATMENT OF NPM-1-DRIVEN ACUTE MYELOID LEUKEMIA (AML) | Jul 4, 2021 | Abandoned |
Array
(
[id] => 17183856
[patent_doc_number] => 20210330741
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-28
[patent_title] => POLYPEPTIDE THERAPEUTICS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/367532
[patent_app_country] => US
[patent_app_date] => 2021-07-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9709
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17367532
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/367532 | POLYPEPTIDE THERAPEUTICS AND USES THEREOF | Jul 4, 2021 | Abandoned |
Array
(
[id] => 18675075
[patent_doc_number] => 20230312646
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => ANTIBACTERIAL PEPTIDES
[patent_app_type] => utility
[patent_app_number] => 18/003421
[patent_app_country] => US
[patent_app_date] => 2021-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15797
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 637
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18003421
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/003421 | ANTIBACTERIAL PEPTIDES | Jun 28, 2021 | Pending |
Array
(
[id] => 18108063
[patent_doc_number] => 20230000943
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-05
[patent_title] => METHOD OF INDUCING SYNAPTOGENESIS BY ADMINISTERING ANGIOTENSIN AND ANALOGUES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/362131
[patent_app_country] => US
[patent_app_date] => 2021-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9325
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17362131
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/362131 | METHOD OF INDUCING SYNAPTOGENESIS BY ADMINISTERING ANGIOTENSIN AND ANALOGUES THEREOF | Jun 28, 2021 | Abandoned |
Array
(
[id] => 18770846
[patent_doc_number] => 20230365647
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-16
[patent_title] => MANNOSE RECEPTOR-DERIVED PEPTIDES FOR NEUTRALIZING PORE-FORMING TOXINS FOR THERAPEUTIC USES
[patent_app_type] => utility
[patent_app_number] => 18/013679
[patent_app_country] => US
[patent_app_date] => 2021-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15585
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18013679
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/013679 | MANNOSE RECEPTOR-DERIVED PEPTIDES FOR NEUTRALIZING PORE-FORMING TOXINS FOR THERAPEUTIC USES | Jun 28, 2021 | Pending |
Array
(
[id] => 20715363
[patent_doc_number] => 12630598
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-05-19
[patent_title] => IL-10 muteins and fusion proteins thereof
[patent_app_type] => utility
[patent_app_number] => 18/001913
[patent_app_country] => US
[patent_app_date] => 2021-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 22
[patent_no_of_words] => 61631
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001913
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/001913 | IL-10 MUTEINS AND FUSION PROTEINS THEREOF | Jun 24, 2021 | Issued |
Array
(
[id] => 18496174
[patent_doc_number] => 20230218727
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-13
[patent_title] => THROMBIN C-TERMINAL PEPTIDES TO TREAT CORONA VIRAL INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 18/001611
[patent_app_country] => US
[patent_app_date] => 2021-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15396
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001611
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/001611 | THROMBIN C-TERMINAL PEPTIDES TO TREAT CORONA VIRAL INFECTIONS | Jun 24, 2021 | Pending |
Array
(
[id] => 17513690
[patent_doc_number] => 11292820
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-04-05
[patent_title] => KV1.3 blockers
[patent_app_type] => utility
[patent_app_number] => 17/356354
[patent_app_country] => US
[patent_app_date] => 2021-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18494
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 78
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17356354
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/356354 | KV1.3 blockers | Jun 22, 2021 | Issued |
Array
(
[id] => 18769431
[patent_doc_number] => 20230364193
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-16
[patent_title] => COMBINED DRUG FOR TREATING CORONARIVUS DISEASE 2019
[patent_app_type] => utility
[patent_app_number] => 18/012025
[patent_app_country] => US
[patent_app_date] => 2021-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4197
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18012025
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/012025 | COMBINED DRUG FOR TREATING CORONARIVUS DISEASE 2019 | Jun 20, 2021 | Abandoned |
Array
(
[id] => 18994630
[patent_doc_number] => 11911447
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-27
[patent_title] => Peptide pharmaceuticals for insulin resistance
[patent_app_type] => utility
[patent_app_number] => 17/349195
[patent_app_country] => US
[patent_app_date] => 2021-06-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 32
[patent_figures_cnt] => 7
[patent_no_of_words] => 33796
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 318
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17349195
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/349195 | Peptide pharmaceuticals for insulin resistance | Jun 15, 2021 | Issued |